Daniel S Chen
Affiliations: | 1998-2006 | Microbiology and Immunology | Stanford University Medical School |
| 2006-2018 | Oncology | Genentech, Inc., San Francisco, CA, United States | |
| 2018- | Development | IGM Biosciences |
Area:
Immunology, Immunotherapy, Oncology, Therapeutics, Antibody EngineeringWebsite:
https://www.linkedin.com/in/daniel-chen-m-d-ph-d-4653842/Google:
"daniel s. chen md phd"Bio:
Parents
Sign in to add mentor| Michael M. C. Lai | grad student | 1992-1996 | USC Keck School of Medicine & HHMI | |
| (Molecular Virology, Immunology, Gene Therapy) | ||||
| Mark M. Davis | post-doc | 2001-2005 | Stanford University & HHMI (Chemistry Tree) | |
| (Cancer Immunology, Human Immunology, Cellular Microarray) | ||||
Children
Sign in to add trainee| Wayne Godfrey | research scientist | 2018- | IGM Biosciences |
| Ed Cha | research scientist | 2012-2018 | Genentech, Inc. |
| Carol E. O'Hear | research scientist | 2014-2018 | Genentech, Inc. (Cell Biology Tree) |
| Alan Sandler | research scientist | 2014-2018 | Genentech, Inc. |
| Bill Grossman | research scientist | 2015-2018 | Genentech, Inc. |
| Herb Hurwitz | research scientist | 2017-2018 | Genentech, Inc. |
Collaborators
Sign in to add collaborator| Ira Mellman | collaborator | 2006- | Genentech, Inc. (Cell Biology Tree) | |
| (Cancer Immunity Cycle, Cancer Immune Set Point, PD-L1/PD-1) | ||||
| Rafi Ahmed | collaborator | 2003-2005 | Emory | |
BETA: Related publications
See more...
Publications
|
You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect. |
| Mellman I, Chen DS, Powles T, et al. (2023) The cancer-immunity cycle: Indication, genotype, and immunotype. Immunity. 56: 2188-2205 |
| Atkins MB, Abu-Sbeih H, Ascierto PA, et al. (2022) Maximizing the value of phase III trials in immuno-oncology: A checklist from the Society for Immunotherapy of Cancer (SITC). Journal For Immunotherapy of Cancer. 10 |
| Mayoux M, Roller A, Pulko V, et al. (2020) Dendritic cells dictate responses to PD-L1 blockade cancer immunotherapy. Science Translational Medicine. 12 |
| Hegde PS, Chen DS. (2020) Top 10 Challenges in Cancer Immunotherapy. Immunity. 52: 17-35 |
| Hamid O, Molinero L, Bolen CR, et al. (2019) Safety, Clinical Activity, and Biological Correlates of Response in Patients With Metastatic Melanoma: Results From a Phase I trial of Atezolizumab. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research |
| Kowanetz M, Zou W, Gettinger SN, et al. (2018) Differential regulation of PD-L1 expression by immune and tumor cells in NSCLC and the response to treatment with atezolizumab (anti-PD-L1). Proceedings of the National Academy of Sciences of the United States of America |
| Chen DS, Hurwitz H. (2018) Combinations of Bevacizumab With Cancer Immunotherapy. Cancer Journal (Sudbury, Mass.). 24: 193-204 |
| McDermott DF, Huseni MA, Atkins MB, et al. (2018) Clinical activity and molecular correlates of response to atezolizumab alone or in combination with bevacizumab versus sunitinib in renal cell carcinoma. Nature Medicine |
| Mariathasan S, Turley SJ, Nickles D, et al. (2018) TGFβ attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells. Nature |
| von Pawel J, Spigel DR, Ervin T, et al. (2018) Randomized Phase II Trial of Parsatuzumab (Anti-EGFL7) or Placebo in Combination with Carboplatin, Paclitaxel, and Bevacizumab for First-Line Nonsquamous Non-Small Cell Lung Cancer. The Oncologist |